PDT Partners LLC grew its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 508,431 shares of the company's stock after purchasing an additional 109,324 shares during the quarter. Roivant Sciences accounts for 0.5% of PDT Partners LLC's portfolio, making the stock its 17th largest position. PDT Partners LLC owned about 0.07% of Roivant Sciences worth $6,015,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of ROIV. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Roivant Sciences in the 4th quarter worth $39,000. GAMMA Investing LLC raised its position in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Roivant Sciences by 84.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares during the period. Institutional investors own 64.76% of the company's stock.
Insider Activity
In other news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,116,345 shares of the company's stock, valued at approximately $11,409,045.90. The trade was a 8.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock worth $14,922,538 in the last ninety days. Corporate insiders own 7.90% of the company's stock.
Roivant Sciences Stock Performance
Shares of ROIV stock traded down $0.10 on Friday, reaching $11.48. 8,767,529 shares of the company's stock traded hands, compared to its average volume of 5,516,819. The company has a market capitalization of $8.19 billion, a P/E ratio of -76.53 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06. The business's 50 day moving average price is $10.40 and its two-hundred day moving average price is $11.14.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research firms have issued reports on ROIV. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Get Our Latest Report on ROIV
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
